FDA clears Rybelsus as a first-line option for type 2 diabetes

The FDA approved a label update for Rybelsus (semaglutide) on January 12, 2023, allowing the once-daily pill to be used as a first-line option for adults with type 2 diabetes, according to a Novo Nordisk announcement ^[1][2]. Before this change, the drug's use was more limited under its original approval, which came on September 20, 2019, as the first oral GLP-1 receptor agonist for type 2 diabetes ^[1][2].

Rybelsus contains semaglutide, the same active ingredient found in the injectable drug Ozempic and the weight-loss injection Wegovy. It works by mimicking a natural hormone called GLP-1, which tells the body to release more insulin and less glucagon when blood sugar is high ^[1][2]. The tablet is taken once a day in the morning, on an empty stomach ^[1][2].

Rybelsus is approved as an add-on to diet and exercise to improve blood sugar control in adults with type 2 diabetes, and separately to lower the risk of major cardiovascular events—death from cardiovascular causes, non-fatal heart attack, or non-fatal stroke—in adults with type 2 diabetes who are at high risk for those events ^[1][2]. The drug's approved tablet strengths at the time were 3 mg, 7 mg, and 14 mg, a formulation later referred to as the R1 formulation ^[1][2].

Common side effects reported in at least 5% of patients include nausea, abdominal pain, diarrhea, decreased appetite, vomiting, and constipation ^[1][2]. The label also lists warnings for acute pancreatitis, complications of diabetic retinopathy, low blood sugar when combined with insulin or certain other diabetes drugs, kidney injury linked to fluid loss, serious digestive side effects, allergic reactions, and the risk of inhaling stomach contents during general anesthesia or deep sedation ^[1][2].

Why it matters for patients

Before this label change, Rybelsus was more often positioned as a later-line therapy, something doctors turned to after trying other diabetes medicines. The 2023 update means a doctor can now consider prescribing Rybelsus as an initial treatment choice, alongside diet and exercise, for adults newly diagnosed with type 2 diabetes ^[1][2]. This gives patients and doctors an oral option earlier in treatment, which may matter to people who prefer not to start with an injectable medicine.

The label update does not change how the drug works, its dosing schedule, or its side effect profile. It also does not mean the drug is right for every patient; the sources do not specify what factors should guide the choice between Rybelsus and other first-line diabetes treatments, so that decision remains one for patients to discuss with their own doctors.

It's worth noting that Rybelsus and Ozempic both contain semaglutide but are approved for different uses and come in different forms—Rybelsus is a tablet, Ozempic is an injection—and patients should not assume the two products are interchangeable based on this label change alone.

What happens next

The sources show that Rybelsus's regulatory story continued well past this 2023 update. On December 9, 2024, a second tablet formulation of Rybelsus, with different strengths (1.5 mg, 4 mg, and 9 mg), was approved ^[1][2]. On October 17, 2025, the FDA approved Rybelsus specifically for cardiovascular risk reduction in high-risk adults with type 2 diabetes ^[1][2]. Later, on January 30, 2026, the FDA approved a name change for that second formulation, rebranding it from Rybelsus to Ozempic tablets ^[1][2]. None of these later developments change the substance of the January 2023 first-line label update itself.